Active Ingredient History
Obatoclax mesylate, also known as GX15-070, is an experimental drug for the treatment of various types of cancer. It was discovered by Gemin X, which was acquired by Cephalon, which has since been acquired by Teva Pharmaceuticals. Several Phase II clinical trials were completed that investigated use of Obatoclax in the treatment of leukemia, lymphoma, myelofibrosis, and mastocytosis. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Burkitt Lymphoma (Phase 1)
Hematologic Neoplasms (Phase 1)
Hodgkin Disease (Phase 2)
Intraocular Lymphoma (Phase 1)
Leukemia (Phase 2)
Leukemia, Hairy Cell (Phase 1)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)
Leukemia, Myeloid, Acute (Phase 2)
Leukemia, Myeloid, Chronic-Phase (Phase 1)
Leukemia, Prolymphocytic (Phase 1)
Lung Neoplasms (Phase 1/Phase 2)
Lymphoma (Phase 1)
Lymphoma, B-Cell, Marginal Zone (Phase 1/Phase 2)
Lymphoma, Follicular (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 1)
Lymphoma, Large-Cell, Anaplastic (Phase 1)
Lymphoma, Large-Cell, Immunoblastic (Phase 1)
Lymphoma, Mantle-Cell (Phase 1/Phase 2)
Lymphoma, Non-Hodgkin (Phase 1)
Lymphoma, T-Cell (Phase 1)
Lymphoma, T-Cell, Peripheral (Phase 1)
Lymphomatoid Granulomatosis (Phase 1)
Mastocytosis, Systemic (Phase 2)
Melanoma (Phase 1/Phase 2)
Multiple Myeloma (Phase 1/Phase 2)
Myelodysplastic Syndromes (Phase 2)
Neoplasms (Phase 1/Phase 2)
Primary Myelofibrosis (Phase 2)
Sezary Syndrome (Phase 1)
Small Cell Lung Carcinoma (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue